Journal of Neuro-Oncology

, Volume 117, Issue 3, pp 459–468 | Cite as

Management of aggressive pituitary adenomas and pituitary carcinomas

Topic Review

Abstract

Pituitary tumors are benign but not uncommonly invade locally into adjacent tissues such as the cavernous sinus and dura. Some of these invasive tumors exhibit varying degrees of resistance to standard therapy and tend to recur. Early prediction of which pituitary tumors will recur and/or exhibit an invasive phenotype remains difficult despite introduction of several tissue-based molecular markers. Management of these recurrent invasive pituitary tumors usually comprises combination medical, surgical and radiation therapy but in some instances is suboptimal. Earlier diagnosis of invasive/recurrent pituitary tumor and application of aggressive multi-modal therapy at presentation may be advantageous in some cases. Clinical trials to develop additional therapeutic options are needed for this subgroup of pituitary tumors. Although it is not yet possible to diagnose at presentation, the subset of pituitary tumors that will become invasive and/or recurrent pituitary tumors, broader use of molecular markers and standardization of histopathological criteria for “atypical” pituitary tumor features have assisted earlier diagnosis. Aggressive therapy early in disease may be warranted and exploration of recently available targeted therapies may improve disease management.

Keywords

Pituitary tumors Aggressive pituitary tumors Pituitary carcinoma 

References

  1. 1.
    Amar AP, Hinton DR, Krieger MD, Weiss MH (1999) Invasive pituitary adenomas: significance of proliferation parameters. Pituitary 2:117–122PubMedCrossRefGoogle Scholar
  2. 2.
    Heaney AP (2011) Clinical review: pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab 96:3649–3660PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99–106PubMedCrossRefGoogle Scholar
  4. 4.
    Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV (1986) Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65:733–744PubMedCrossRefGoogle Scholar
  5. 5.
    Kontogeorgos G (2005) Classification and pathology of pituitary tumors. Endocrine 28:27–35PubMedCrossRefGoogle Scholar
  6. 6.
    Kovacs K (2006) The 2004 WHO classification of pituitary tumors: comments. Acta Neuropathol 111:62–63PubMedCrossRefGoogle Scholar
  7. 7.
    Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV, Cusimano M (2009) Ki-67 in Pituitary Neoplasms: A Review-Part I. Neurosurgery 65:429–437PubMedCrossRefGoogle Scholar
  8. 8.
    Lim S, Shahinian H, Maya MM, Yong W, Heaney AP (2006) Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 7:518–520PubMedCrossRefGoogle Scholar
  9. 9.
    Tanizaki Y, Jin L, Scheithauer BW, Kovacs K, Roncaroli F, Lloyd RV (2007) p53 gene mutations in pituitary carcinomas. Endocr Pathol 18:217–222PubMedCrossRefGoogle Scholar
  10. 10.
    Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38:765–769PubMedCrossRefGoogle Scholar
  11. 11.
    Mete O, Ezzat S, Asa SL (2012) Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49:R69–R78PubMedCrossRefGoogle Scholar
  12. 12.
    Kaltsas GA, Grossman AB (1998) Malignant pituitary tumors. Pituitary 1:69–81PubMedCrossRefGoogle Scholar
  13. 13.
    Gadelha MR, Trivellin G, Hernández Ramírez LC, Korbonits M (2013) Genetics of pituitary adenomas. Front Horm Res 41:111–140PubMedCrossRefGoogle Scholar
  14. 14.
    Korbonits M, Storr H, Kumar AV (2012) Familial pituitary adenomas—who should be tested for AIPmutations? Clin Endocrinol (Oxf) 77:351–356CrossRefGoogle Scholar
  15. 15.
    Sheldon WH, Golden A, Bondy PK (1954) Cushing’s syndrome produced by a pituitary basophil carcinoma with hepatic metastases. Am J Med 17:134–142PubMedCrossRefGoogle Scholar
  16. 16.
    Ezzat S, Zheng L, Asa SL (2004) Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol Endocrinol 18:2543–2552PubMedCrossRefGoogle Scholar
  17. 17.
    Kawamoto H, Kawamoto K, Mizoue T, Uozumi T, Arita K, Kurisu K (1996) Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis. Acta Neurochir 138:1442–1448PubMedCrossRefGoogle Scholar
  18. 18.
    Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fevre-Montagne M, Rey C, Figarella-Baranger D, Raverot G, Belin MF, Lachuer J, Trouillas J (2007) A diagnostic marker set for invasion, proliferation and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer 14:887–900PubMedCrossRefGoogle Scholar
  19. 19.
    Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TP, Bronstein MD, Melmed S (1999) Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84:761–767PubMedCrossRefGoogle Scholar
  20. 20.
    Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J, Trouillas J (2010) Prognostic factors in prolactin pituitary tumors: clinical, histological and molecular data from a series of 94 patients with a long prospective follow-up. J Clin Endocrinol Metab 95:1708–1716PubMedCrossRefGoogle Scholar
  21. 21.
    Vroonen L, Jaffrain-Rea M-L, Petrossians P, Tamagno G, Chanson P, Vilar L, Borson-Chazot F, Naves LA, Brue T, Gatta B, Delemer B, Ciccarelli E, Beck-Peccoz P, Caron P, Daly AF, Beckers A (2012) Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 167:651–662PubMedCrossRefGoogle Scholar
  22. 22.
    Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90:4405–4410PubMedCrossRefGoogle Scholar
  23. 23.
    Bonert V, Frohman LA (2007) Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy. Pituitary 10:283–289PubMedCrossRefGoogle Scholar
  24. 24.
    Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM, Pasireotide B2305 Study Group (2012) A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 366:914–924. doi:10.1056/NEJMoa1105743 PubMedCrossRefGoogle Scholar
  25. 25.
    Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER Jr (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114:336–344PubMedCrossRefGoogle Scholar
  26. 26.
    Ilyess Z, Wierinckx A, Vasiljevic A, Jan M, Trouillas J, Francois P (2013) Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management. Pituitary 16:515–522CrossRefGoogle Scholar
  27. 27.
    Swords FM, Allen CA, Plowman PN, Sibtain A, Evanson J et al (2003) Stereotactic radiosurgery XVI: a treatment for previously irradiated pituitary adenomas. J Clin Endocrinol Metab 88:5334–5340PubMedCrossRefGoogle Scholar
  28. 28.
    Loeffler JS, Shih HA (2011) Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 96:1992–2003PubMedCrossRefGoogle Scholar
  29. 29.
    Rowland NC, Aghi MK (2010) Radiation treatment strategies for acromegaly. Neurosurg Focus 29:110CrossRefGoogle Scholar
  30. 30.
    Sheehan JP, Pouratian N, Steiner L, Laws ER, Vance ML (2011) Gamma knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg 114:303–309PubMedCrossRefGoogle Scholar
  31. 31.
    Castinetti F, Nagai M, Dufour H, Kuhn JM, Morange I, Jaquet P, Conte-Devolx B, Regis J, Brue T (2007) Gamma knife radiosurgery is a successful adjunctive treatment in Cushing’s disease. Eur J Endocrinol 156:91–98PubMedCrossRefGoogle Scholar
  32. 32.
    Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Eng J Med 364:514–523CrossRefGoogle Scholar
  33. 33.
    Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Eng J Med 343:1350–1354CrossRefGoogle Scholar
  34. 34.
    Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M (2009) Temozolomide treatment if a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 161:631–637PubMedCrossRefGoogle Scholar
  35. 35.
    Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE (2007) Temozolomide therpay in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 38:185–189PubMedCrossRefGoogle Scholar
  36. 36.
    Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC (2008) MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115:261–262PubMedCrossRefGoogle Scholar
  37. 37.
    Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Francois P, Jouanneau E, Passagia JG, Bernier M, Cornelius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T (2010) Temozolomide treatment of aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95:4592–4599PubMedCrossRefGoogle Scholar
  38. 38.
    Vaughan NJ, Laroche CM, Goodman I, Davies MJ, Jenkins JS (1985) Pituitary Cushing’s disease arising from a previously non-functional corticotrophic chromophobe adenoma. Clin Endocrinol (Oxf) 22:147–153CrossRefGoogle Scholar
  39. 39.
    Kasperlik-Zaluska AA, Wislawski J, Kaniewska J, Zborzil J, Frankiewicz E, Zgliczyński S (1987) Cytostatics for acromegaly. Marked improvement in a patient with an invasive pituitary tumour. Acta Endocrinol (Copenh) 116:347–349Google Scholar
  40. 40.
    Neff LM, Weil M, Cole A et al (2007) Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10:81–86PubMedCrossRefGoogle Scholar
  41. 41.
    Syro LV, Uribe H, Penagos LC et al (2006) Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65:552–553CrossRefGoogle Scholar
  42. 42.
    Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD (2009) Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery 64:E773–E774PubMedCrossRefGoogle Scholar
  43. 43.
    Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M (2009) Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 161:631–637PubMedCrossRefGoogle Scholar
  44. 44.
    Syro LV, Scheithauer BW, Ortiz LD et al (2009) Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. Hormones (Athens) 8:303–306CrossRefGoogle Scholar
  45. 45.
    Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML, Thorner MO, Laws ER Jr, Lopes MB (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcomes with DNA methylation and MGMT expression. J Clin Endocrinol Metab 95:E280–E290PubMedCrossRefGoogle Scholar
  46. 46.
    Zemoura I, Wierinckx Vasiljevic A, Jan M, Trouillas J, Francois P (2013) Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management. Pituitary 16:515–522. doi:10.1007/s11102-012-0448-y CrossRefGoogle Scholar
  47. 47.
    Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K (2008) Prospective study of prolactinomas in 150 patients. J Clin Endo Metab 93:4721–4727CrossRefGoogle Scholar
  48. 48.
    Delgrange E, Sassolas G, Perin G, Jm Trouillas (2005) Clinical and histological correlations in prolactinomas, with specifi reference to bromocriptine resistance. Acta Neurochir 147:751–757PubMedCrossRefGoogle Scholar
  49. 49.
    Filopanti M, Barbieri AM, Angioni AR, Colao A, Gasco V, Grottoli S, Peri A, Baglioni S, Fustini MF, Pigliaru F, Monte PD, Boretta G, Ambrosi B, Jaffrain-Rea ML, Gasperi M, Brogioni S, Cannavo S, Mantovani G, Beck-Peccoz P, Lania A, Spada A (2008) Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharmacogenomics J 8:357–363PubMedCrossRefGoogle Scholar
  50. 50.
    Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: aclinical and proliferation marker study. J Clin Endocrinol Metab 82:2102–2107PubMedGoogle Scholar
  51. 51.
    Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S (1999) Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5:1317–1321PubMedCrossRefGoogle Scholar
  52. 52.
    Stefaneanu L, Kovacs K, Horvath E, Lloyd RV, Buchfelder M, Fahlbusch R, Smyth H (1994) In situ hybridisation study of estrogen receptor messenger ribonucleic acid in human adenohypophysial cells and pituitary adenomas. J Clin Endocrinol Metab 78:83–88PubMedGoogle Scholar
  53. 53.
    Wu ZB, Zheng WM, Su ZP, Chen Y, Wu JS, Wang CD, Lin C, Zeng YJ, Zhuge QC (2010) Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior. J Neurooncol 99:25–32PubMedCrossRefGoogle Scholar
  54. 54.
    Gillam MP, Middler S, Freed DJ, Molitch ME (2002) The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endo Metab 87:4447–4451CrossRefGoogle Scholar
  55. 55.
    George DH, Scheithauer BW, Kovacs K et al (2003) Crooke’s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 27:1330–1336PubMedCrossRefGoogle Scholar
  56. 56.
    Rotondo F, Cusimano M, Scheithauer BW, Coire C, Horvath E, Kovacs K (2012) Atypical, invasive, recurring Crooke cell adenoma of the pituitary. Hormones 11:94–100PubMedGoogle Scholar
  57. 57.
    Jenkins PJ, Trainer PJ, Plowman PN, Shand WS, Grossman AB, Wass JA, Besser GM (1995) The long-term outcome after adrenalectomy and prophylactic radiotherapy in adrenocorticotrophin-dependant Cushings syndrome. J Clin Endocrinol Metab 80:165–171PubMedGoogle Scholar
  58. 58.
    Assie G, Bahurel H, Coste J, Silvera S, Kujas M, Dugue MA, Karray F, Dousset B, Bertherat J, Legmann Bertagna X (2007) Corticotroph tumor progression after adrenalectomy in Cushings disease: a reappraisal of Nelson’s syndrome. J Clin Endocrinol Metab 92:172–179PubMedCrossRefGoogle Scholar
  59. 59.
    Ohta S, Nishizawa S, Oki Y, Yokoyama T, Namba H (2002) Significance of absent prohormone convertase 1/3 i inducing clinically silent corticotroph pituitary adenoma of subtype I-immunohistochemical study. Pituitary 4:221–223CrossRefGoogle Scholar
  60. 60.
    Cooper O, Melmed S (2012) Suclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab 26:447–460PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Batisse M, Raverot G, Maqdasy S, Durando X, Sturm N, Montoriol PF, Kemeny JL, Chazal J, Trouillas J, Tauveron I (2013) Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide. Cancer Invest 31:190–196PubMedCrossRefGoogle Scholar
  62. 62.
    McCutcheon IE, Piper DR, Fuller GN, Benjamin RS, Friend KE, Gagel RF (2000) Pituitary carcinoma containing gonadotrophins: treatment by radical excision and cytotoxic chemotherapy: case report. Neurosurgery 46:1233–1239PubMedCrossRefGoogle Scholar
  63. 63.
    Lopes MB, Scheithauer BW, Schiff D (2005) Pituitary carcinoma: diagnosis and treatment. Endocrine 28:115–121PubMedCrossRefGoogle Scholar
  64. 64.
    Saeger W, Lubke D (1996) Pituitary Carcinomas. Endocr Pathol 7:21–35PubMedCrossRefGoogle Scholar
  65. 65.
    Scheithauer BW, Fereidooni F, Horvath E, Kovacs K, Robbins P, Tews D, Henry K, Pernicone P, Gaffrey TA Jr, Meyer FB, Young WF Jr, Fahlbusch R, Buchfelder M, Lloyd RV (2001) Pituitary Carcinoma: an ultrastructural study of eleven cases. Ultrastruct Pathol 25:227–242PubMedCrossRefGoogle Scholar
  66. 66.
    Cartwright DM, Miller TR, Nasr AJ (1994) Fine-needle aspiration biopsy of pituitary carcinoma with cervical lymph node metastases: a report of two cases and review of the literature. Diagn Cytopath 11:68–73CrossRefGoogle Scholar
  67. 67.
    Ayuk J, Natarajan G, Geh I (2005) Pituitary carcinoma with a single metastasis causing cervical spinal cord compression: case report. J Neurosurg Spine 2:349–353PubMedCrossRefGoogle Scholar
  68. 68.
    Pivot X, Bedaria N, Thiery-Vuillemin A, Espie M, Marty M (2011) Combining molecular targeted therapies: clinical experience. Anti-Cancer drugs Epub PMID 21467916Google Scholar
  69. 69.
    Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513PubMedCrossRefGoogle Scholar
  70. 70.
    Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, Lapparelli M, Scanarini M, Degli Uberti EC (2010) Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 95:968–97660PubMedCrossRefGoogle Scholar
  71. 71.
    Moin T, Yong WH, Heaney AP. Atypical adenoma, pituitary carcinoma and the role of chemotherapy in the management of refractory pituitary adenoma. In: Schwartz T, Anand VK (eds) Endoscopic Pituitary Surgery. Thieme Publishers, New YorkGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of MedicineDavid Geffen School of Medicine at UCLALos AngelesUSA
  2. 2.Department of NeurosurgeryDavid Geffen School of Medicine at UCLALos AngelesUSA

Personalised recommendations